http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110384708-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-606 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-606 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2019-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110384708-B |
| titleOfInvention | Mesalazine colon-targeted controlled-release tablet and preparation method thereof |
| abstract | The invention belongs to the technical field of mesalazine controlled release preparations, and particularly relates to a mesalazine colon-targeted controlled release tablet and a preparation method thereof. The mesalazine colon-targeted controlled release tablet consists of a tablet core layer and a controlled release layer positioned outside the tablet core layer, wherein the tablet core layer consists of mesalazine and an auxiliary material pyrodextrin, and the weight average molecular size R of the auxiliary material pyrodextrin h 1.5-2.8nm, and 80-98% of solubility, wherein the controlled release layer adopts weight average molecular size R h 8-12nm, and 1.2-4.0% of solubility. Compared with other controlled release preparations, the mesalazine colon-targeted controlled release tablet with the double-layer tablet structure is prepared by using pyrodextrins with different characteristics as auxiliary materials, and has high biological safety by only using starch-based pyrodextrins as auxiliary materials; the tablet is prepared only by a conventional tabletting process, has simple processing process and is easy for large-scale industrial production. |
| priorityDate | 2019-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.